Buprenorphine and Boceprevir: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Boceprevir
No brand names on recordBuprenorphine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Boceprevir is a hepatitis C medicine that slows down a liver enzyme (called CYP3A4) that normally helps clear buprenorphine from your body. When that enzyme is blocked, more buprenorphine can build up in your blood.
Because buprenorphine is an opioid, higher levels can make its effects stronger and last longer. That can mean feeling extra sleepy, very drowsy, or in serious cases breathing that becomes slow or shallow. This is worth taking seriously, but the good news is your care team can manage it by adjusting your dose and watching you more closely. Please don't change either medicine on your own, just talk with your pharmacist or doctor.
Mechanism: Boceprevir is a CYP3A4 inhibitor; buprenorphine is a CYP3A4 substrate (parent compound is active, not a prodrug). Inhibition reduces buprenorphine metabolism, increasing plasma exposure.
Effect: Increased buprenorphine concentrations with risk of prolonged opioid effects, including sedation and respiratory depression. Severity major; evidence probable; onset unspecified.
Management:
- If starting boceprevir, consider reducing buprenorphine dose until stable, monitor frequently for sedation/respiratory depression.
- On boceprevir discontinuation, anticipate need to increase buprenorphine dose; monitor for withdrawal.
- For subQ depot buprenorphine, monitor for over-medication; consider a formulation allowing precise titration if needed.
What happens
Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
Taking buprenorphine together with a CYP3A4 inhibitor can raise buprenorphine plasma concentrations, potentially producing extended opioid effects such as respiratory depression. When a patient on buprenorphine must also receive a CYP3A4 inhibitor, it may be appropriate to lower the buprenorphine dose until drug effects stabilize, with regular monitoring for sedation and respiratory depression. Conversely, if a CYP3A4 inhibitor is stopped in a patient on buprenorphine therapy, an increase in the buprenorphine dose until stable effects are reached may be warranted, along with monitoring for symptoms of opioid withdrawal2. Should dose adjustment prove impossible once the CYP3A4 inhibitor is no longer present, switch the patient to a buprenorphine formulation that allows finer dose titration. For patients moving from a regimen of transmucosal buprenorphine given alongside CYP3A4 inhibitors, confirm through monitoring that the plasma buprenorphine level delivered by subQ buprenorphine is sufficient. When a patient already receiving subQ buprenorphine needs a CYP3A4 inhibitor, watch for indications of over-medication. If buprenorphine toxicity or overdose signs and symptoms develop and the concomitant drug cannot be reduced or withdrawn, decrease the buprenorphine dose. When the available doses do not allow the intended dose to be reached, stop the treatment and manage the patient using a buprenorphine formulation that supports more precise dose adjustments 1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medicines exactly as prescribed unless your care team tells you otherwise. This combination can be managed with tailored dosing and closer monitoring.
- Your buprenorphine dose may need to be adjusted and individualized by your care team, often lowered while you are on boceprevir, then raised back when boceprevir stops.
- Your team may monitor you more closely for excess sedation or slowed breathing, and for withdrawal symptoms once boceprevir is stopped.
- With long-acting (injectable) buprenorphine, a switch to a formulation allowing finer dose adjustments may be considered.
Tell your pharmacist or prescriber right away about unusual drowsiness, confusion, or slow/shallow breathing.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) Whether concurrently administered CYP3A4 inhibitors alter buprenorphine exposure in individuals receiving subQ buprenorphine has not been investigated; nevertheless, these interactions have been demonstrated in studies that used transmucosal buprenorphine. Buprenorphine's effects may vary according to the route of administration 1.
Common questions
Can I take Buprenorphine and Boceprevir together?
Boceprevir can raise buprenorphine levels and prolong its opioid effects, so your care team may lower your buprenorphine dose and watch you more closely for sedation or slowed breathing. Keep both medicines as prescribed and report unusual drowsiness or breathing changes promptly. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Boceprevir interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Boceprevir interaction managed?
Keep taking both medicines exactly as prescribed unless your care team tells you otherwise. This combination can be managed with tailored dosing and closer monitoring. Your buprenorphine dose may need to be adjusted and individualized by your care team, often lowered while you are on boceprevir, then raised back when boceprevir stops. Your team may monitor you more closely for excess sedation or s… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Boceprevir need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Boceprevir
Keep reading about Buprenorphine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist